Company · CIK 0001703647 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
Korro Bio, Inc. · KRRO
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 11, 2026 SForm 4 → | Sep 15, 4:15 pm EDT | Jean Francois FormelaDirector | 48,690 | $14.09 | $686,177 | 132,650 | −26.9% | 10b5-1 |
| Sep 11, 2026 SForm 4 → | Sep 14, 4:05 pm EDT | Oliver DolanSenior Vice President, Finance | 5 | $13.72 | $69 | 16,241 | −0.03% | 10b5-1 |
| Sep 8, 2026 SForm 4 → | Sep 10, 4:05 pm EDT | Oliver DolanSenior Vice President, Finance | 7,353 | $13.51 | $99,368 | 16,246 | −31.2% | 10b5-1 |
| Aug 26, 2026 SForm 4 → | Aug 28, 4:30 pm EDT | Jean Francois FormelaDirector | 300 | $13.96 | $4,188 | 141,002 | −0.21% | 10b5-1 |
| Aug 19, 2026 SForm 4 → | Aug 21, 4:20 pm EDT | Jean Francois FormelaDirector | 28,468 | $14.00 | $398,552 | 141,053 | −16.8% | 10b5-1 |
| Aug 11, 2026 SForm 4 → | Aug 13, 5:04 pm EDT | Jean Francois FormelaDirector | 2,143 | $13.96 | $29,916 | 145,937 | −1.45% | 10b5-1 |
| Aug 6, 2026 PForm 4 → | Aug 13, 9:54 am EDT | Lynx1 Capital Management LP +110% Owner | 6,684 | $11.79 | $78,809 | 1,544,980 | +0.43% | late |
| Aug 4, 2026 SForm 4 → | Aug 5, 4:05 pm EDT | Ram AiyarPresident and CEO, Director | 5,802 | $10.84 | $62,917 | 69,046 | −7.75% | |
| Jul 15, 2026 AForm 4 → | Jul 17, 7:14 am EDT | Loic A VincentChief Scientific Officer | 7,500 | — | — | 25,797 | — | |
| Jul 15, 2026 AForm 4 → | Jul 17, 7:11 am EDT | Oliver DolanSenior Vice President, Finance | 5,500 | — | — | 23,599 | — | |
| Jul 15, 2026 AForm 4 → | Jul 17, 7:08 am EDT | Jeffrey CerioGeneral Counsel | 6,500 | — | — | 41,793 | — | |
| Jul 15, 2026 AForm 4 → | Jul 17, 7:05 am EDT | Todd ChappellChief Operating Officer | 7,500 | — | — | 24,464 | — | |
| Jul 2, 2026 SForm 4 → | Jul 7, 6:04 pm EDT | Jean Francois FormelaDirector | 110,023 | $14.02 | $1,542,970 | 146,305 | −42.9% | 10b5-1 |
Reported at this company — derivatives (options, RSUs, warrants)
No reported derivative activity in this period.